Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases

키워드

참고문헌 (35)

1. Galderisi S, "Interplay among psychopathologic variables, personal resources, context-related factors, and real-life functioning in individuals with schizophrenia : a network analysis", JAMA Psychiatry, 75, pp.396~404 (2018)
2. Iasevoli F, "Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones", Prog Neuropsychopharmacol Biol Psychiatry, 65, pp.34~48 (2016)
3. De Berardis D, "Safety and efficacy of combined clozapine-azathioprine treatment in a case of resistant schizophrenia associated with Behçet's disease : a 2-year follow-up", Gen Hosp Psychiatry, 35, pp.213~ (2013)
4. De Berardis D, "Treatment resistance in psychiatry: risk factors, biology, and management", pp.349~367 (2019), Springer
5. De Berardis D, "Safety of antipsychotics for the treatment of schizophrenia : a focus on the adverse effects of clozapine", Ther Adv Drug Saf, 9, pp.237~256 (2018)
6. Stahl SM, "Mechanism of action of cariprazine", CNS Spectr, 21, pp.123~127 (2016)
7. Misiak B, "Cariprazine-a novel antipsychotic drug and its place in the treatment of schizophrenia", Psychiatr Pol, 52, pp.971~981 (2018)
8. Chhatlani A, "Use of cariprazine in psychiatric disorders : a systematic review", Ann Clin Psychiatry, 30, pp.326~334 (2018)
9. McCormack PL, "Cariprazine : first global approval", Drugs, 75, pp.2035~2043 (2015)
10. "Neuropsychopharmacol Hung", 2019, 103~118
11. cariprazine : an in vivo positron emission tomography study in nonhuman primates, "Synapse", 2013, 258~264
12. Corponi F, "Novel antipsychotics specificity profile : a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone", Eur Neuropsychopharmacol, 29, pp.971~985 (2019)
13. Citrome L, "Cariprazine : chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability", Expert Opin Drug Metab Toxicol, 9, pp.193~206 (2013)
14. Ragguett RM, "Cariprazine for the treatment of bipolar depression : a review", Expert Rev Neurother, 19, pp.317~323 (2019)
15. Domenico De Berardis, "Rapid improvement of obsessive-compulsive disorder associated with schizophrenia with cariprazine add-on in a subject under paliperidone long-acting injection", International Clinical Psychopharmacology, 35(2), pp.113~118 (2019), Ovid Technologies (Wolters Kluwer Health)[DOI]
16. De Berardis D, "The novel antipsychotic cariprazine(RGH-188) : state-of-the-art in the treatment of psychiatric disorders", Curr Pharm Des, 22, pp.5144~5162 (2016)
17. Orsolini L, "Cariprazine (RGH-188): a new pharmacological target option for the treatment of schizophrenia, bipolar disorders and depression?", Minerva Psichiatr, 58, pp.17~25 (2017)
18. Huang M, "The role of dopamine D3 receptor partial agonism in cariprazineinduced neurotransmitter efflux in rat hippocampus and nucleus accumbens", J Pharmacol Exp Ther, 371, pp.517~525 (2019)
19. Gründer G, "Cariprazine, an orally active D2", D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression, 2010, pp.11, 823~832
20. Calabrese F, "The role of dopamine D3 receptors in the mechanism of action of cariprazine", CNS Spectr, pp.1~9 (2019)
21. Zhao MJ, "Efficacy and acceptability of cariprazine in acute exacerbation of schizophrenia : meta-analysis of randomized placebo-controlled trials", J Clin Psychopharmacol, 38, pp.55~59 (2018)
22. Fleischhacker W, "The efficacy of cariprazine in negative symptoms of schizophrenia : Post hoc analyses of PANSS individual items and PANSS-derived factors", Eur Psychiatry, 58, pp.1~9 (2019)
23. Frank A, "Binding kinetics of cariprazine and aripiprazole at the dopamine D3 receptor", Sci Rep, 8, pp.12509~ (2018)
24. Werner FM, "Safety of antipsychotic drugs : focus on therapeutic and adverse effects", Expert Opin Drug Saf, 13, pp.1031~1042 (2014)
25. Moritz AE, "Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds", Cell Signal, 41, pp.75~81 (2018)
26. Stahl SM, "Drugs for psychosis and mood : unique actions at D3, D2, and D1 dopamine receptor subtypes", CNS Spectr, 22, pp.375~384 (2017)
27. Werner FM, "Neural networks in neurological and psychiatric diseases", Curr Pharm Des, 25, pp.374~375 (2019)
28. Herman A, "Involvement of 5-HT1A and 5-HT2A receptors but not  2-adrenoceptors in the acute electrophysiological effects of cariprazine in the rat brain in vivo", Mol Pharmacol, 94, pp.1363~1370 (2018)
29. Nakamura T, "Clinical pharmacology study of cariprazine(MP-214)in patients with schizophrenia(12-week treatment)", Drug Des Devel Ther, 10, pp.327~338 (2016)
30. Thorn CF, "PharmGKB summary : clozapine pathway, pharmacokinetics", Pharmacogenet Genomics, 28, pp.214~222 (2018)
31. Schoretsanitis G, "A comprehensive review of the clinical utility of and a combined analysis of the clozapine", norclozapine ratio in therapeutic drug monitoring for adult patients, 2019, pp.12, 603~621
32. Tóth K, "Potential role of patients' CYP3A-status in clozapine pharmacokinetics", Int J Neuropsychopharmacol, 20, pp.529~537 (2017)
33. Barnes SA, "The effects of cariprazine and aripiprazole on PCP-induced deficits on attention assessed in the 5-choice serial reaction time task", Psychopharmacology(Berl), 235, pp.1403~1414 (2018)
34. Halaris A, "Metabolic syndrome reversal with cariprazine", J Clin Psychopharmacol, 39, pp.413~416 (2019)
35. Nasrallah HA, "The safety and tolerability of cariprazine in long-term treatment of schizophrenia : a post hoc pooled analysis", BMC Psychiatry, 17, pp.305~ (2017)

관련 논문AI추천